Lumiradx hba1c test achieves ce mark, addresses growing global need for diabetes screening and monitoring with its next-generation point of care diagnostic platform

Rapid microfluidic immunofluorescence assay intended for the monitoring of individuals with diabetes, and as an aid in screening and identifying patients who may be at risk for developing diabetes the automated, quantitative fingerstick assay is run on the highly portable lumiradx platform and designed for near-patient testing with connected results in under seven minutes rising global rates of diabetes presents growing need for broader access and an easier, more connected solution for hba1c testing in community-based healthcare settings such as primary care and retail pharmacy available on the same point of care (poc) platform as lumiradx's high sensitivity sars-cov-2 antigen, flu a/b, rsv, sars-cov-2 antibody, sars-cov-2 antigen pool, sars-cov-2 ag ultra as well as inr, d-dimer and crp tests* london , may 26, 2022 /prnewswire/ -- lumiradx limited (nasdaq: lmdx), a next-generation point of care diagnostics company, today announced its hba1c test has achieved ce marking. used with the lumiradx platform, the test provides results in under seven minutes from sample application for the monitoring of individuals with diabetes, and as an aid in screening and identifying patients who may be at risk for developing diabetes, all at the point of care.
LMDX Ratings Summary
LMDX Quant Ranking